ストックスクリーナーアプリを入手
1.76
7.32%
0.12
アフターアワーズ：
1.72
-0.04
-2.27%
Engene Therapeutics Inc (ENGN) 最新ニュース
EnGene bladder cancer data shows promise, but durability questions remain - MSN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of enGene Therapeutics Inc.ENGN - Sahm
Dow Dips 350 Points; US Foods Posts Downbeat Earnings - Sahm
Law firm probes enGene Therapeutics over stock plunge after disappointing cancer trial results - Pluang
Pomerantz Law Firm Investigates Claims On Behalf of Investors of enGene Therapeutics Inc.ENGN - FinancialContent
EnGene Therapeutics (ENGN) price target decreased by 64.55% to 8.72 - MSN
enGene (ENGN) filing: Cormorant and Bihua Chen report 0 shares - Stock Titan
BML Investment Partners reports 9.95% stake in enGene Holdings (ENGN) - Stock Titan
ENGN SEC FilingsenGene Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
UBS Adjusts EnGene Price Target to $2 From $9, Maintains Neutral Rating - Moomoo
UBS Maintains EnGene Therapeutics(ENGN.US) With Hold Rating, Cuts Target Price to $2 - Moomoo
Why is enGene Therapeutics stock falling Friday? - MSN
BML Investment Partners discloses 7.8% stake in enGene (ENGN) on 05/08/2026 - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
A Look At enGene Therapeutics (ENGN) Valuation After LEGEND Trial Update And Legal Investigations - Yahoo Finance
ENGN Plunges As enGene Faces LEGEND Trial Setback And Legal Probe - timothysykes.com
enGene Therapeutics Inc. (ENGN) Discusses Pivotal Cohort Data from LEGEND Trial of Detalimogene in High-Risk NMIBCSlideshow (NASDAQ:ENGN) 2026-05-09 - Seeking Alpha
Why Is enGene Therapeutics Stock Falling Friday? - Sahm
enGene Stock Plunges As LEGEND Trial Downgrades Mount - timothysykes.com
enGene Therapeutics Inc.Common Stock (ENGN) Stock Price, News, Quote & History - FinancialContent
enGene Therapeutics (ENGN) Is Down 80.6% After Mixed Phase 2 Bladder Cancer Data UpdateWhat's Changed - simplywall.st
Guggenheim downgrades EnGene Therapeutics (ENGN) - MSN
enGene Holdings (ENGN) Gets a Buy from H.C. Wainwright - The Globe and Mail
enGene Bladder Cancer Data Shows Promise, but Durability Questions Remain - sharewise.com
enGene Therapeutics (ENGN) Is Down 76.3% After Mixed LEGEND Phase 2 Durability Data Release Has The Bull Case Changed? - Yahoo Finance
[ARS] enGene Therapeutics Inc. SEC Filing - Stock Titan
enGene Therapeutics (NASDAQ: ENGN) details 2026 virtual shareholder meeting - Stock Titan
ENGN Stock Collapses As Street Slashes Targets After Trial Shock - StocksToTrade
Guggenheim Downgrades EnGene Holdings to Neutral From Buy - Moomoo
EnGene cancer sales forecast cut after new data widen gap to J&J - Fierce Biotech
A Quick Look at Today's Ratings for EnGene Therapeutics(ENGN.US), With a Forecast Between $2 to $6 - Moomoo
Citizens Downgrades EnGene to Market Perform From Market Outperform - Moomoo
Oppenheimer Downgrades EnGene Holdings to Market Perform From Outperform - Moomoo
Morgan Stanley Downgrades EnGene Holdings to Equalweight From Overweight - Moomoo
Engene stock rating cut to Perform by Oppenheimer on trial data By Investing.com - Investing.com South Africa
Piper Sandler cuts Engene Holdings stock rating on trial concerns By Investing.com - Investing.com South Africa
Piper Sandler cuts Engene Holdings stock rating on trial concerns - Investing.com UK
Engene stock rating cut to Perform by Oppenheimer on trial data - Investing.com Nigeria
Citizens downgrades Engene Holdings stock rating on weaker trial data By Investing.com - Investing.com UK
Guggenheim downgrades Engene stock rating on weaker trial data By Investing.com - Investing.com Nigeria
Raymond James downgrades Engene Holdings stock rating on trial results By Investing.com - Investing.com UK
enGene reports 54% response rate in bladder cancer trial By Investing.com - Investing.com South Africa
0.98%
0.12%
大文字化:
|
ボリューム (24 時間):